The research compound in Zepbound^®

Zepbound^® is a chronic weight management medicine from Eli Lilly and Company. Its active compound is Tirzepatide — which is what this catalogue supplies, as a research material.

This is not Zepbound^®, and NOVALYTE LABS has no affiliation with Eli Lilly and Company. We supply the compound Tirzepatide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Zepbound^® is a trademark of Eli Lilly and Company, referenced here only to identify the compound.

Zepbound is Eli Lilly’s brand for tirzepatide in weight management. The active compound is identical to that in Mounjaro; the brands differ by approved indication rather than by molecule.

Tirzepatide activates the GIP and GLP-1 receptors simultaneously, combining two incretin pathways in one peptide.

The compound is listed here as a research material with batch documentation, not as the branded medicine.

Tirzepatide in this catalogue

Other brands using Tirzepatide

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.